Outcome of tumor lysis syndrome in pediatric patients with hematologic malignancies – a single-center experience from Pakistan

2016 ◽  
Vol 14 (11) ◽  
pp. 457-465
Author(s):  
Armaghan-e-Rehman Mansoor ◽  
Mohammad Faizan Zahid ◽  
Mujtaba Mubashir ◽  
Zehra Fadoo ◽  
Anwar ul Haq ◽  
...  
Keyword(s):  
Pediatric Patients ◽  
Tumor Lysis Syndrome ◽  
Hematologic Malignancies ◽  
Single Center ◽  
Tumor Lysis ◽  
Single Center Experience

Randomized Clinical Trial of Rasburicase Administered as a Standard Fixed Five Days Dosing Vs a Single Dose Followed by as Needed Dosing in Adult Patients with Hematologic Malignancies at Risk for Developing Tumor Lysis Syndrome.

Blood ◽  
2009 ◽  
Vol 114 (22) ◽  
pp. 105-105 ◽  
Author(s):  
Saroj Vadhan-Raj ◽  
Luis Fayad ◽  
Michelle Fanale ◽  
Barbara Pro ◽  
Alma Rodriguez ◽  
...  
Keyword(s):  
Uric Acid ◽  
Single Dose ◽  
High Risk ◽  
Serum Creatinine ◽  
Plasma Levels ◽  
Pediatric Patients ◽  
Tumor Lysis Syndrome ◽  
Hematologic Malignancies ◽  
Tumor Lysis ◽  
Tnf Α

Abstract Abstract 105 Tumor lysis syndrome (TLS) is a potentially life threatening complication resulting from massive lysis of malignant cells and most frequently observed in patients with rapidly proliferating, bulky, and chemo-sensitive malignancies. The prevention and management of TLS includes hydration and reduction in the levels of serum uric acid by drugs that decrease production or increase excretion of uric acid. Rasburicase is a recombinant urate oxidase that rapidly reduces the levels of uric acid by enhancing the conversion of existing uric acid into allantoin which is more soluble in urine than uric acid. Rasburicase is approved in the USA for the treatment of pediatric patients at high risk for developing TLS, to be administered at a dose of 0.15 to 0.2 mg/kg once daily for 5 days. Although, activity has been seen with lower doses and shorter duration of treatment, the optimal dosing of rasburicase has not been established for adults. The purpose of this study was to evaluate the efficacy of rasburicase (0.15 mg/kg) administered as a single dose followed by as needed (max 5 doses over 5 days) as compared to standard fixed 5-days dosing in patients with hematologic malignancies at risk for TLS. The patients were stratified based on their risk for TLS and randomized 1:1 to rasburicase administered as a single dose followed by as needed (Arm A) or fixed daily dose x 5 days (Arm B). Sixty six patients were enrolled; 20 had > 2-fold LDH levels and 9 had above-normal serum creatinine. 64 patients received at least one dose of rasburicase and were evaluable for response [24 high risk with mean baseline uric acid levels, 9.8 (7.6–16.1 mg/dL) and 40 potential risk with uric acid, 5.3 (2.4-7.4 mg/dL)]. All patients normalized their uric acid levels at 4 hours after the first dose; 83% to an undetectable level (<0.7 mg/dL). On Arm B (fixed 5-days dosing), all patients (n=34, 100%) had a sustained response, as defined by the normalization of uric acid levels in 48 hours and its maintenance within normal range for 6 days. On Arm A, all except for 4 patients (all 4 high risk for TLS) had a sustained response (26 of 30, 87%) to a single dose of rasburicase. Four of 11 patients from the high risk group required a second dose around day 4 for uric acid levels >7.5 mg/dL. Serum creatinine normalized in all patients by day 5. The treatment was well tolerated, except for one incident of methemoglobinema and hemolytic anemia in a patient found to have G6PD deficiency. Since high uric acid levels have been associated with elevated cytokine levels, we examined the effects of treatment on plasma cytokines. At baseline, high risk patients showed increased TNF-α and IL-6 plasma levels. There was a marked decrease in the plasma levels of TNF-α (from mean 14.2 to 6.4 pg/ml, p<0.0001), and IL-6 (from 11.2 to 8 pg/mL, p=0.05) during treatment. Conclusion: Rasburicase is a highly effective uricolytic agent for prevention and management of TLS. This study demonstrates that it is feasible to decrease the duration of administration of rasburicase at the approved dose of 0.15 mg/kg. The majority of patients responded to a single dose of the agent, and only a small subset at high risk for TLS required a second dose. Disclosures: Vadhan-Raj: Sanofi Aventis: Honoraria, Research Funding. Off Label Use: Rasburicase is indicated for the initial management of plasma uric acid levels in pediatric patients with leukemia, lymphoma, and solid tumor malignancies who are receiving anti-cancer therapy expected to result in tumor lysis and subsequent elevation of uric acid. The approved administration dose, route, and schedule are 0.15-0.20 mg/kg IV infusion for 5 days, respectively.

Robotic versus open pyeloplasty in pediatric patients: a single center experience in Saudi Arabia

2018 ◽  
Vol 70 (5) ◽  
Author(s):  
Noor N. Junejo ◽  
Santiago Vallasciani ◽  
Ahmad Alshammari ◽  
Hossam Aljallad ◽  
Saeed Alshahrani ◽  
...  
Keyword(s):  
Saudi Arabia ◽  
Pediatric Patients ◽  
Single Center ◽  
Single Center Experience ◽  
Open Pyeloplasty

Neuroblastoma with intracerebral metastases and the need for neurosurgery: a single-center experience

2020 ◽  
Vol 25 (1) ◽  
pp. 51-56
Author(s):  
Steffen Fleck ◽  
Sascha Marx ◽  
Clara Bobak ◽  
Victoria Richter ◽  
Stephan Nowak ◽  
...  
Keyword(s):  
Pediatric Patients ◽  
Neurosurgical Procedures ◽  
Normal Brain ◽  
Indications For Surgery ◽  
Single Center ◽  
Neurosurgical Procedure ◽  
Oncological Treatment ◽  
Single Center Experience ◽  
Stage 4 ◽  
Neurosurgical Treatment

OBJECTIVEIntracerebral metastases in neuroblastoma patients are rare, and information about the indication for and the outcome of neurosurgical procedures in this setting is scarce in the literature. The authors’ aim in the present study was to report a single-center experience with the neurosurgical treatment of intracerebral metastases in neuroblastoma.METHODSThis study is a retrospective single-center analysis of all neurosurgical strategies used in the treatment of intracerebral metastases in neuroblastoma patients.RESULTSBetween 2009 and 2017, 237 pediatric patients (94 girls, 143 boys) with a mean age of 39 months at diagnosis were treated for neuroblastoma. Five (2.1%) of the 237 patients had a neurosurgical procedure for intracerebral metastases. The metastases occurred a mean of 46 months after initial diagnosis. All of these patients had neuroblastoma stage 4. Indications for surgery were recurrent metastases after initial successful oncological treatment or progression of the metastasis under oncological treatment as well as deterioration of neurological function. Intraoperatively, the tumor usually had a distinguishable dissection plane but was infiltrative to adjacent nerves in some spots. Mean overall survival after the neurosurgical procedure was 22 months. Furthermore, in another 3 patients, a neurosurgical procedure was done for an intracranial but extracerebral metastasis.CONCLUSIONSNeurosurgical procedures for intracerebral metastases in neuroblastoma patients are rare and were performed in 2.1% of patients in the present study. Intracerebral metastases occurred during disease progression, and the prognosis after surgery was very limited. The main indications for surgery were rapid neurological deterioration or recurrence of the metastasis after initial successful oncological treatment. Intraoperatively, the metastases usually had a distinguishable dissection plane from the normal brain tissue.

Blunt renal trauma-induced hypertension in pediatric patients: a single-center experience

2021 ◽  
Author(s):  
Marios Marcou ◽  
Matthias Galiano ◽  
Jörg Jüngert ◽  
Oliver Rompel ◽  
Torsten Kuwert ◽  
...  
Keyword(s):  
Pediatric Patients ◽  
Renal Trauma ◽  
Single Center ◽  
Single Center Experience ◽  
Induced Hypertension
Sign in / Sign up

Export Citation Format

Share Document